Any current/future capex/capital investment/strategic investment?

Planned capex of approximately INR 2,000 crores over the next 5 years focused on: - Brownfield expansions including new lines, lyophilizers, and additional warehouse capacity. - Investment in BFS (Blow-Fill-Seal) technology lines. - New ophthalmic line with suspension capability. - Capex towards CDMO contracts. Next year capex expected to be more than INR 400 crores. Asset turn targeted at more than 3x due to high-value business expectations. Expansion driven by: - Increased demand and expected growth. - Current capacity constraints in lyophilizers and ophthalmic products. - Need

Future growth expectations in sales/revenue/volumes?

Company expects overall growth of 12%-13% as a minimum confidence level for FY '27 base business. Mid-teens growth (around 15%) guidance remains, contingent on product launches and regulatory approvals, especially for Dalba in the U.S. Dalba is approved in 6 European countries and launched in December; U.S. approval expected in February, pending additional data submission. Additional demand from Europe expected to offset potential shortfalls in the U.S. Dalba launch. Cenexi shows strong momentum with 14%-21% revenue growth in FY ’26 and plans capacity expansions; aiming to maintain positive EB

Future growth expectations in earnings/operating earnings/profits/EPS?

Gland Pharma targets a 15% organic CAGR over the next 5 years for base business growth. Revenue growth driven by upcoming product launches, CDMO contract ramp-ups, and new capacities. Cartridge fill and finish capacity to expand significantly from 40 million to 140 million units, supporting volume growth. EBITDA growth supported by cost efficiency initiatives, operating leverage, and synergy benefits (e.g., from Cenexi). Cenexi is on a turnaround path, with positive EBITDA trends expected to sustain and improve its contribution. Investment of INR 2,000 crores over 5 years for capacity expansio

Current/ Expected Orderbook/ Pending Orders?

Gland Pharma is experiencing higher volumes in the U.S., about 19% year-on-year increase, driven by new contracts signed, including GPO contracts. The company is in discussions with insulin manufacturers for significant orders to utilize the 40 million capacity pen cartridge line. For the new 100 million capacity line, expected to be ready by Q2 after validation, the existing signed contracts are sufficient to fill the capacity. There's a focus on CDMO contracts with commercial quantities and take-or-pay agreements, indicating clear revenue visibility over 2-3 years. Cenexi's annualized revenu

IN US

Sale is live|00:00:00left today

Gland Pharma LtdQ4 FY27Pharmaceuticals & Biotechnology

Gland Pharma Ltd Q4 FY27 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹2,315P/E: 29.5Market Cap: ₹30.8K CrSector: Pharmaceuticals & Biotechnology

Management growth scorecard

Revenue

Category 3

Margin

Category 3

Fundraise

N/A

Order

Yes

Capex

Yes

2 of 4 growth signals are positive.

Full analysis

Revenue guidance

Category 3

→Company expects overall growth of 12%-13% as a minimum confidence level for FY '27 base business.
→Mid-teens growth (around 15%) guidance remains, contingent on product launches and regulatory approvals, especially for Dalba in the U.S.
→Dalba is approved in 6 European countries and launched in December; U.S. approval expected in February, pending additional data submission.
→Additional demand from Europe expected to offset potential shortfalls in the U.S. Dalba launch.
→Cenexi shows strong momentum with 14%-21% revenue growth in FY ’26 and plans capacity expansions; aiming to maintain positive EBITDA and medium- to long-term growth.
→Capacity constraints in lyophilizers and liquid vials likely within 1-1.5 years, with ongoing investments to support volume growth.
→Investments of INR 2,000 crores over next 5 years, including Brownfield expansions, BFS lines, and ophthalmic lines, to enhance capacity and drive volume/value growth.
→Faster CMS approvals in Europe expected to further boost growth beyond 12%-13%.

Margin guidance

Category 3

→Gland Pharma targets a 15% organic CAGR over the next 5 years for base business growth.
→Revenue growth driven by upcoming product launches, CDMO contract ramp-ups, and new capacities.
→Cartridge fill and finish capacity to expand significantly from 40 million to 140 million units, supporting volume growth.
→EBITDA growth supported by cost efficiency initiatives, operating leverage, and synergy benefits (e.g., from Cenexi).
→Cenexi is on a turnaround path, with positive EBITDA trends expected to sustain and improve its contribution.
→Investment of INR 2,000 crores over 5 years for capacity expansions (including ophthalmic, BFS, vial, lyo, and suspension lines) aimed at high-value, high-turn businesses.
→Hurdle rate for new investments is approximately 20% IRR, indicating disciplined capital allocation.
→CDMO and GLP-1 business expected to scale up, enhancing future profitability and utilization.
→ESOP costs may vary but are expected to decrease for current grants in the near term.

3 more insights locked — sign up free to unlock

Fundraise plans

Based on the information on pages 9 to 16 of the document "1274812.pdf": - There is no explicit mention of any current or planned fundraising through debt or equity. - The company plans to invest approximately INR 2,000 crores over the next 5 years for capacity expansion, including Brownfield expansions, new BFS line, and ophthalmic line. - Capex for next year is expected to be over INR 400 crores, funded internally based on asset turns of more than 3x. - No discussions or announcements related to issuing new equity or raising debt were stated during the periods covered. - The company's hurdle rate for investments is 20% IRR, reflecting internal funding discipline. Hence, no clear indication of new fundraising through debt or equity is reported in the current discussions.

Order book

Yes

→Gland Pharma is experiencing higher volumes in the U.S., about 19% year-on-year increase, driven by new contracts signed, including GPO contracts.
→The company is in discussions with insulin manufacturers for significant orders to utilize the 40 million capacity pen cartridge line.
→For the new 100 million capacity line, expected to be ready by Q2 after validation, the existing signed contracts are sufficient to fill the capacity.
→There's a focus on CDMO contracts with commercial quantities and take-or-pay agreements, indicating clear revenue visibility over 2-3 years.
→Cenexi's annualized revenue is around EUR 200 million, with positive EBITDA expected going forward.
→Dalba product launch has been approved in 6 European countries, with U.S. approval pending, potentially adding to orders.
→Additional demand from Europe may offset potential U.S. approval delays, indicating a healthy pending orderbook.

Capex plans

Yes

→Planned capex of approximately INR 2,000 crores over the next 5 years focused on:
→ - Brownfield expansions including new lines, lyophilizers, and additional warehouse capacity.
→ - Investment in BFS (Blow-Fill-Seal) technology lines.
→ - New ophthalmic line with suspension capability.
→ - Capex towards CDMO contracts.
→Next year capex expected to be more than INR 400 crores.
→Asset turn targeted at more than 3x due to high-value business expectations.
→Expansion driven by:
→ - Increased demand and expected growth.
→ - Current capacity constraints in lyophilizers and ophthalmic products.
→ - Need to stay ahead in emerging technology platforms (BFS).
→Capex supports base business growth, a strong pipeline of CDMO contracts, and development of complex, differentiated, and higher-value products.
→Aim is to maintain strong ROCE, cash generation, and efficient working capital management.

How does Gland Pharma Ltd rank vs peers in Pharmaceuticals & Biotechnology?

Pro feature

1Gland Pharma Ltd

Rev 3Mar 3

See full Pharmaceuticals & Biotechnology sector rankings

Want more stocks like Gland Pharma Ltd?

Build an AI portfolio filtered by sector, market cap, and growth rank. Takes 2 minutes.

Build my portfolio